Strong Innovation Focus Chiasma's development of its proprietary Transient Permeability Enhancer (TPE®) technology and successful Phase 3 clinical trials for Mycapssa indicate a robust pipeline of innovative drug delivery solutions, creating opportunities to partner or supply complementary technologies and expand product offerings.

European Market Entry With submissions for marketing authorization of Mycapssa to the European Medicines Agency, there is significant potential to support distribution, commercialization, and regulatory assistance as they penetrate the European market, especially within endocrinology and rare disease segments.

Expanding Rare Disease Portfolio Chiasma's focus on treatments for rare conditions like acromegaly positions them as a strategic partner for companies offering diagnostics, supportive care, or complementary therapies targeting similar patient populations in the rare disease landscape.

Recent Acquisition Leverage Following Amryt Pharma’s acquisition of Chiasma, there are opportunities to collaborate on integrated solutions, joint marketing efforts, or to expand distribution channels within the rare and orphan disease sectors across global markets.